Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule, the very small tubes in the kidney that filter the blood and remove waste products. RCC is the most common type of kidney cancer in adults, responsible for approximately 80% of cases. It is also known to be the most lethal of all the genitourinary tumors. Initial treatment is most commonly a radical or partial nephrectomy and remains the mainstay of curative treatment. Where the tumor is confined to the renal parenchyma, the 5-year survival rate is 60-70%, but this is lowered considerably where metastases have spread. It is relatively resistant to radiation therapy and chemotherapy, although some cases respond to immunotherapy. Targeted cancer therapies such as sunitinib, temsirolimus, bevacizumab, interferon-alpha, and sorafenib have improved the outlook for RCC (progression-free survival), although they have not yet demonstrated improved survival.
Read more about Renal Cell Carcinoma: Signs and Symptoms, Classification, Epidemiology, Diagnosis, Prognosis, Treatment, Metastatic Renal Cell Carcinoma, Adjuvant Therapy in Renal Cell Carcinoma, History
Famous quotes containing the word cell:
“It is plain that there is no separate essence called courage, no cup or cell in the brain, no vessel in the heart containing drops or atoms that make or give this virtue; but it is the right or healthy state of every man, when he is free to do that which is constitutional to him to do.”
—Ralph Waldo Emerson (1803–1882)